fda panel give green light new amgen biotech drug u food drug administr advisori panel recommend friday amgen inc newest biotechnolog drug approv use cancer patient drug call granulocyt coloni stimul factor spur product white blood cell help chemotherapi patient fight infect analyst think becom blockbust product eventu 200 million 450 million year seller amgen base thousand oak final fda approv g csf virtual certain said jim mccamant editor medic technolog stock letter berkeley expect drug market within month news ignit amgen stock surg 2 75 friday record 59 25 per share amgen new drug competit thursday immunex seattl base biotechnolog concern also receiv favor review fda panel new white blood cell product call gm csf howev immunex drug expect approv treat bone marrow transplant patient amgen drug would approv cancer patient undergo chemotherapi cancer market much larger mccamant said insur compani said tend reimburs new drug use accord fda recommend mccamant initi expect amgen domin white blood cell drug market drug amgen second biotechnolog product first gene splice protein call erythropoietin epo produc red blood cell treat chronic anemia patient kidney diseas epo sale run annual rate 300 million profit drug come rate nearli 50 million year